Difference between revisions of "IEICE, et al, IEICE ESS Fundam Rev (2020), cited as Ref 51 in DOI:10.1007/s11886-020-01292-3 (Q10560)"
Jump to navigation
Jump to search
(Created claim: Page(s) (P105): 177-, #quickstatements; #temporary_batch_1592505331951) |
(Created claim: Issue (P104): 3, #quickstatements; #temporary_batch_1592505440125) |
||
| Property / Issue | |||
| + | 3 | ||
| Property / Issue: 3 / rank | |||
| + | Normal rank | ||
Revision as of 18:38, 18 June 2020
Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
IEICE, et al, IEICE ESS Fundam Rev (2020), cited as Ref 51 in DOI:10.1007/s11886-020-01292-3
|
Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.
|
Statements
Q10356 (Deleted Item)
0 references
Overview of planned or ongoing studies of drugs for the treatment of COVID-19 (English)
0 references
IEICE
0 references
2020
0 references
IEICE ESS Fundam Rev
0 references
177-
0 references
3
0 references
